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KEY POINTS 
•  Inhaled corticosteroids (ICS) have led to considerably improved asthma control and reduced asthma mortality 
in the Western world over the last 2 decades, particularly in combating T-helper type 2-driven inflammation 
featuring mast cell and eosinophilic airway infiltration. 
•  Their effect on innate immunity-driven neutrophilic inflammation is rather poor and their ability to prevent 
airway remodeling and accelerated lung decline is highly controversial. 
•  Although ICS remain pivotal drugs in asthma management, research is needed to find drugs complementary to 
the combination ICS/long-acting β2-agonist in refractory asthma and perhaps a new class of drugs as a first-line 
treatment in mild to moderate noneosinophilic asthma. 
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INTRODUCTION 
There was a time when asthmatics had their symptoms treated with a regular short-acting bronchodilator and 
theophylline, while reserving the use of systemic corticosteroids for severe exacerbations and for chronic 
maintenance treatment of the most severe patients. The emergence of corticosteroids suitable for the inhaled 
route in the 1970s followed by convincing clinical trials during the late 1980s has dramatically changed the 
picture of asthma treatment. The class of inhaled corticosteroids (ICS) has rapidly demonstrated its superiority 
over other classes of drugs used in asthma.
1
 The first Global Initiative for Asthma consensus in the early 1990s 
further highlighted the importance of the role of ICS in asthma treatment.
2
 There is no doubt that the reduced 
mortality and morbidity of asthma observed since the 1990s is, in a large part, related to the regular use of ICS as 
the mainstay of asthma treatment. Yet some studies have pointed out the variability of the response to ICS in 
patients with asthma, suggesting that ICS administered alone might not be the best drug for all patients.
3
 
FROM EARLY PROMISE TO THE TIME OF CERTITUDE 
The first studies using inhaled hydrocortisone and prednisone in asthma were disappointing. It became apparent 
that this was because of the inappropriate chemical structure of prednisone, which has first to be metabolized to 
become pharmacologically effective, and the lack of topical activity of these corticosteroids. The chemical 
transformation of prednisone to increase both lipophilicity and interaction with glucocorticosteroid receptor 
made it possible to find compounds that were suitable for the inhaled route. Early studies in the 1970s used 
inhaled beclomethasone dipropionate and triamcinolone acetate in moderate to severe asthma and showed that 
these drugs were effective in improving lung function and reducing symptoms despite tapering oral 
corticosteroids.
4-6
 The introduction of ICS dramatically and effectively changed the conventional approach to 
asthma therapy. The institution of ICS made it possible to replace, in most of the patients, the chronic use of oral 
corticosteroids, thereby avoiding side effects that were often severe and debilitating.
7
 Furthermore, it soon 
seemed to be an inverse relationship between the rate of hospitalization for acute asthma exacerbation and the 
sales of ICS. In a cohort study of more than 13,000 patients with asthma, ICS were shown to be more effective 
than theophylline in reducing the hospitalization rate as long as they were taken regularly.
8
 In a population-based 




The interest of ICS in the milder form of the disease was established later. Thefirst pivotal study proving the 
superiority of ICS over β2-agonists as a maintenance treatment dates back to 1991. Haahtela and colleagues10 
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demonstrated that the regular use of inhaled budesonide at the dosage of 1200 µg/d was by far superior to the 
regular use of terbutaline in improving the day-to-day peak expiratory flow rate and reducing asthma symptoms 
and as-needed relief bronchodilator usage. It is also by this time that the fundamental inflammatory nature of 
asthma was recognized even in the mildest form of the disease.
11
 Asthma has then been regarded as a chronic 
airway inflammatory disease featuring eosinophil and mast cell airway wall infiltration as a consequence of a T-
helper type 2 (Th2)-driven inflammatory process. The role of cytokines, such as interleukin 4 (IL-4) and IL-5, 
were highlighted as key cytokine in immunoglobulin E (IgE) synthesis from B cells and eosinophil survival 
respectively.
12
 The role of chemokines for eosinophils, like eotaxin, was also demonstrated in asthma.
13
 Regular 
treatment with ICS was shown to reduce the number of T-lymphocytes, eosinophils, and mast cells
14
 and restore 
epithelial integrity
15
 in bronchial biopsies. Numerous studies showed that regular treatment with ICS sharply and 
quickly reduces the percentage of eosinophils contained in the sputum from patients with asthma.
16-20
 Therefore, 
corticosteroids were thought to be effective in asthma treatment because of their ability to repress the release of 
Th2 cytokine from lymphocytes
21
 and eotaxin from epithelial cells,
22
 thereby depleting airways from eosinophils 
and mast cells. More recently, it has been shown that corticosteroids are highly effective in inhibiting the 
transcription factor GATA3, which drives Th2 cells and the release of Th2 cytokines.
23
 Therefore, ICS have 
been regarded as the perfect treatment of asthma leading to control for the peculiar airway inflammation while 
minimizing the systemic side effects because of their local action. Even in the mildest form of the disease, severe 
exacerbations may occur and ICS were shown to be extremely effective in preventing  them.
24
  This  important 
property of ICS can lead us to think of this drug class as a disease-modifying drug in asthma. However, it soon 
appeared that ICS, even administrated at high doses, might not treat all facets of asthma or control all patients 
with asthma. 
CORTICOSTEROIDS AND LOSS OF LUNG FUNCTION 
Accelerated lung decline is a well-known feature of chronic obstructive pulmonary disease (COPD) and it is 
generally accepted that ICS fails to prevent it when patients continue to smoke.
25 
The recognition that patients 
with asthma also have an accelerated lung function decline regardless of smoking
26,27
 and despite regular 
treatment with ICS
24,28
 has questioned the role of this class of drugs as a disease-modifying agent in asthma. In 
contrast to what has been shown for airway inflammation, it has been extremely difficult to convincingly 
demonstrate an effect of corticosteroids on airway remodeling. These effects require higher doses and sustained 
administration to show small changes in airway structure.
29,30
 On the other hand, it has been demonstrated that in 




 These observations led 
to the concept that airway inflammation and airway remodeling may be largely independent processes and, 
consequently, governed by different cytokine and growth factor networks, with corticoids being essentially 
active against the Th2 inflammatory component.
33
 The recent observation that bronchoconstriction by itself may 
be a trigger for airway remodeling is of great importance because it may have potential significant implications 
for a treatment strategy to prevent lung function decrease.
34
 In this view, it would seem logical to combine 
corticoids and long-acting-β2-agonist (LAESA) at the early stages of asthmatic disease to maximize the 
bronchopro-tecting effect and reduce the chance to evolve toward airway remodeling. 
THE RECOGNITION OF REFRACTORY ASTHMA 
The Gaining Optimal Asthma Control study showed that most patients with asthma can become largely 
asymptomatic when regularly treated by a combination ICS/LABA.
35
 This therapeutic strategy also proved to be 
efficient in preventing asthma exacerbation in most patients. Yet a small fraction of patients with asthma, called 
patients with refractory or severe asthma, escape to that treatment. Severe or refractory asthma is generally 
thought to affect 1 % to 5% of all patients with asthma and accounts for most asthma costs.
35-39
 This phenotype is 
defined by inadequate asthma control despite a high dose of inhaled corticosteroids or the need for oral 
corticosteroids, often associated with other controller medication, such as LABA, leukotriene receptor 
antagonist, or theophylline.
40,41
 By itself, this phenotype clearly points out the inability of corticosteroids to 
control disease expression in some patients with asthma. Early studies showed that these patients had consistent 
persistent eosinophilic or neutrophilic airway inflammation despite regular antiinflammatory treatment,
42-46
 
indicating that corticosteroids were unable to control the underlying airway inflammation. These studies have 
certainly contributed to the emergence of the concept of an eosinophilic versus neutrophilic asthma phenotype, a 
concept that has extended beyond the sole group of refractory asthma (see later discussion). In severe asthma, 
this concept has proved to be useful in asthma management. It was clearly demonstrated that persistent 
eosinophilic inflammation may still be responsive to an increase in the dose of inhaled or systemic 
corticosteroids in terms of lung function and symptom improvement
47
 and chiefly in terms of the reduction of 
exacerbation.
48,49
 These important studies point to a reduced sensitivity rather than to a real resistance to 
eosinophilic inflammation to corticosteroids. Reduced eosinophil apoptosis in induced sputum despite a high 
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dose of inhaled corticosteroids was shown to be related to disease severity.
50 
The molecular reason why severe 
eosinophilic inflammation may persist despite heavy treatment with corticosteroids remains unknown, but there 
are several molecular mechanisms for corticosteroid resistance in asthma.
51
 
THE MOLECULAR CONCEPT OF CORTICOSTEROID RESISTANCE 
It has been well demonstrated that corticosteroids have a positive interaction with β2-agonists at the molecular 
level. Indeed, corticosteroids increase the transcription of the β2-agonist receptor, resulting in increased 
expression of the receptor at the cell surface.
52,53
 On the other hand, there is growing evidence to show that β2-
agonists enhance the action of corticosteroids, particularly through enhancing the translocation of glucocorticoid 
receptor (GR), therefore, increasing the binding of GR to the glucocorticoid response element at the gene level.
54
 
However, patients with severe asthma have a poor response to corticosteroids, even when combined to β2-
agonists, which necessitates the need for high doses and a few patients are completely resistant. Patients with 
asthma who smoke are also relatively corticosteroid resistant and require increased doses of corticosteroids for 
asthma control.
55
 Several molecular mechanisms have now been identified to account for corticosteroid 
resistance in severe asthma.
51
 In smoking patients with asthma and patients with severe asthma, there is a 
reduction in activity and expression of the critical nuclear enzyme histone deacetylase-2, which prevents 
corticosteroids from switching off activated inflammatory genes.
56-58
 In steroid-resistant asthma, other 
mechanisms may also contribute to corticosteroid insensitivity, including the reduced translocation of GR as a 
result of phosphorylation by p38 mitogen-activated protein (MAP) kinase
59
 and abnormal histone acetylation 
patterns.
60
 A proposed mechanism is an increase in GR-β, which prevents GR binding to DNA,61 but there is 
little evidence that this would be sufficient to account for corticosteroid insensitivity because the amounts of GR-
β are too low.62 Th17 cells may be involved in driving neutrophilic inflammation in some patients with severe 
asthma and these cells seem to be largely corticosteroid resistant.
63,64
 
COMPLEMENTARY TREATMENT TO CORTICOSTEROIDS IN REFRACTORY ASTHMA 
Although abundantly used in COPD, tiotropium has been poorly validated in asthma treatment. A recent study 
conducted in patients with uncontrolled asthma, despite a moderate dose of inhaled beclomethasone, showed that 
tiotropium was at least equivalent to salmeterol in improving asthma lung function and symptoms.
65
 Further 
studies focusing on patients with more severe asthma and looking at exacerbations as the major outcome are now 
warranted to validate the use of a long-acting anticholinergic in refractory asthma. 
In those patients with refractory asthma, with moderately elevated total serum IgE and sensitization to a 
perennial allergen, omalizumab, a humanized monoclonal antibody against IgE, has proved to be effective in 
reducing the exacerbation rate and improving quality of life,
66,67
 although part of the effect seen in clinical 
practice in quality-of life-improvement is likely to be caused by a placebo effect and a careful follow-up of 
patients inherent in the mode of drug administration.
68
 Like for corticosteroids, the clinical benefit of 
omalizumab might be partly explained by a reduction of eosinophilic inflammation.
69,70
 The major drawback of 
this currently available treatment is the high cost, which weakens the cost-effectiveness relationship.
71 
Cost-
effectiveness, however, depends on how hospitalization for exacerbation may be prevented; a drug that may 
reduce the hospitalization rate in high-risk patient is likely to be cost-effective. 
Some studies indicate a continuous synthesis and release of Th2 cytokines, such as IL-4 and IL-5, both at a 
systemic
72
 and airway level
73 
despite the regular treatment with inhaled corticoids. Yet there is no sign of 
reduced activity of corticosteroids in vitro to inhibit cytokine release from circulating leukocytes in those 
patients with refractory asthma.
72
 The importance of IL-5 in driving the persistent systemic and airway 
eosinophilic inflammation has recently been demonstrated by the efficacy of mepolizumab, an anti-IL-5 
monoclonal antibody, to further decrease eosinophilic inflammation in those patients with refractory asthma 
despite a high dose of corticosteroids.
74,75
 The clinical relevance of the persistent eosinophilic inflammation is 
demonstrated by the reduction in the exacerbation rate and the improvement in quality of life observed in those 
patients receiving mepolizumab,
74
 even if no effect is observed on airway caliber and bronchial 
hyperresponsiveness,
74 
which is confirmatory of earlier studies with other anti-IL-5 antibodies.
76,77
 Importantly, 
mepolizumab made it possible to taper and sometimes suppress the use of oral corticosteroids.
75
 A recent 16-
week study using reslizumab, a new monoclonal antibody against IL-5, has shown a significant improvement in 
forced expiratory volume in the first second of expiration in patients with moderate to severe eosinophilic 
asthma displaying prominent reversibility to a β2-agonist.78 
Anti-tumor necrosis factor (TNF)-α is an established treatment in chronic inflammatory diseases, like Crohn 
disease or rheumatoid arthritis. Despite early promising pilot studies,
79-82
 treatments that target TNF-α have 
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generally proved to be disappointing in improving asthma control in patients with refractory asthma. This 





The studies focusing on neutrophilic inflammation in refractory asthma have been limited so far. One study 
using clarithromycin has shown a significant reduction of sputum neutrophil count and sputum elastase together 
with an improved quality of life.
85
 However, there was no improvement in asthma control or airway caliber. On 
the other hand, targeting neutrophils may theoretically prove to be a dangerous strategy in patients with 
refractory asthma by increasing their susceptibility to infections.
86
 A recent study in COPD, another disease with 
prominent neutrophilic inflammation,
87,88
 has shown a reduction of the exacerbation rate by regular treatment 
with azithromycin.
89 
The mechanisms by which macrolide antibiotics might be effective remain elusive. Whether 
it is through antiinflammatory activity or by limiting airway colonization with typical or atypical bacterial 
pathogens remains to be investigated.
90
 Clearly, in refractory asthma, further studies conducted on a longer-term 
period are needed to investigate the impact of macrolides on asthma exacerbation rate. Other treatments in 
development, mainly for COPD, also target neutrophilic inflammation, including antagonists against the 
chemokine receptor CXCR2, phosphodiesterase-4 inhibitors, and p38 MAP kinase inhibitors.
91
 
Bronchial thermoplasty (BT) is an innovative non-pharmacologic treatment approach to reduce the 
bronchoconstrictor response in asthma. Although technically demanding, BT has been shown to improve asthma 
control and quality of life and to be safe in patients with moderate to severe asthma.
92-94
 A recent multicenter 
study confirmed the ability of BT to improve control and quality of life in patients with refractory asthma and 
showed that BT resulted in a reduced severe exacerbation rate in the posttreatment period.
95
 
EMERGENCE OF THE CONCEPT OF ASTHMA PHENOTYPE IN MILD TO MODERATE ASTHMA 
The development of the technique of induced sputum has been a key step in the appearance of the concept of 
inflammatory phenotype in asthma. Although it confirmed the eosinophilic inflammation as a prominent feature 
of asthma,
96
 which relates to disease severity,
43,50,72
 it also showed that up to 50% of patients with asthma failed 
to exhibit this eosinophilic phenotype.
97,98
 Almost half of them are characterized by intense neutrophilic 
inflammation
99
 but the other half fails to show any abnormal granulocytic inflammation despite excessive lung 
function variability. The importance of these phenotypes is that the underlying molecular mechanisms are 
different. Although the eosinophilic phenotype is likely to reflect ongoing adaptive immunity in response to an 
allergen with Th2 cytokine IL-4, IL-5, and IL-13 playing a key role, the neutrophilic phenotype is thought to 
reflect innate immune system activation in response to pollutants or infectious agents.
100,101
 Therefore, it is 
conceivable that the 2 phenotypes actually require different therapeutic molecular approaches. 
Exhaled nitrous oxide (NO) is increased in patients with asthma
102
 and particularly in those with eosinophilic 
inflammation.
103
 A large-scale study conducted in routine has shown that a fractional exhaled NO threshold of 
around 40 ppb (measured at an exhaled flow of 50 mL/s) is predictive of eosinophilic inflammation in patients 
with asthma even though this threshold may be decreased by smoking and a high dose of ICS. The threshold was 
27 ppb in smoking asthmatics and 28 ppb in those receiving at least 1000 µg/d of fluticasone (considered as high 
dose ICS). Moreover the threshold can be as low as 15 ppb in a non atopic smoking patient receiving high dose 
of ICS.
104
 However, we lack an equivalent noninvasive marker for neutrophilic inflammation. The development 
of breath print by chromatography and mass spectrometry is a promising tool to approach these cellular 
phenotypes. 
PREDICTING FACTORS OF CLINICAL RESPONSE TO CORTICOSTEROIDS 
The results of large, randomized controlled clinical trials have perhaps masked for too long the fact that the 
response of ICS is variable in patients with asthma.
105
 As pointed out earlier, the response to ICS is characterized 
by a high intraindividual repeatability and a high interindividual variability, with up to 40% of patients showing 
no short-term response to the treatment.
3
 The presence of a persistent airway eosinophilic inflammation seems to 
be a good predicting factor for a short-term response to ICS 105-109 Alternatively, a high exhaled NO level (>47 
ppb according to the studies) is predictive of a good response to ICS in patients with chronic respiratory 
symptoms regardless of the disease label.
110
 Furthermore, the presence of a Th2 cytokine profile in the airways 
seems to be needed to have rapid lung function improvement with ICS.
111 
Even if a convincing response may be 
sometimes observed
112
 in those with high exhaled NO (>33 ppb),
107
 noneosinophilic asthma generally exhibits a 
limited response to ICS
113
 and the response seems to be particularly poor in those patients exhibiting intense 
airway neutrophilic inflammation,
99 
which is reminiscent of the inability of ICS to control airway inflammation 
in COPD.
114,115
 A recent study has highlighted the importance of the genetic background in the improvement of 
lung function following chronic treatment with ICS. A functional variant of glucocorticosteroid transcript 1 gene 
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was found to be associated with a decreased response to ICS in several randomized clinical trials.
116
 In the 
studies published so far, the corticosteroid response has been assessed either by lung function or quality-of-life 
improvement over a short-term period (a few weeks). There is, however, a lack of evidence to support that 
denying treatment with ICS over a long-term period in some patients does not place them at risk of severe 
exacerbation. Clearly, new long-term prospective studies with asthma exacerbation as the main outcome are 
needed to clarify this important point. 
CORTICOSTEROIDS IN CLINICAL PRACTICE 
Like in many chronic diseases, poor compliance to maintenance treatment has been shown to be a major issue in 
asthma.
117
 Poor inhalation technique is a further impediment in achieving a successful treatment with inhaled 
therapies in patients with asthma.
117
 Because corticosteroids do not bring acute relief for asthma symptoms, it is 
likely to play a role in poor compliance. Although ICS have clearly demonstrated superior efficacy to leukotriene 
receptor antagonists with respect to most clinical outcomes in randomized controlled trials, a recent field study 
conducted in the United Kingdom has not confirmed this superiority in terms of asthma control.
118
 The 
emergence of the SMART concept (Symbicort as a maintenance and relief therapy) has been an interesting 
paradigm that allows patients to inhale a dose of corticosteroids whenever he or she feels the need to use a rapid-
acting bronchodilator. The concept that has been extensively validated in randomized controlled clinical trials
119
 
has also been shown to be valid in daily clinical practice.
120
 The SMART approach has been shown to be 
particularly efficient in reducing the rate of severe asthma exacerbation. 
NEW CLASS DRUG IN DEVELOPMENT 
There are several new drugs for asthma currently in development that may be suited more for patients who do 
not respond well to corticosteroids.
91 
Several cytokines are involved in the pathophysiology of asthma, including 
Th2 cytokines. Anti-IL-5 antibodies (mepolizumab, reslizumab) are currently in clinical trials for severe 
eosinophilic asthma that is resistant to corticosteroids, as discussed earlier. IL-13 is increased in severe asthma 
and causes corticosteroid resistance, so it is a logical target. Currently, anti-IL-13 antibodies, such as lebrikizu-
mab, have been disappointing with little physiologic effect and no effect on symptoms or exacerbations.
121
 
Blocking antibodies to other cytokines, including IL-9, IL-25, IL-33, and thymus stromal lymphopoietin, are also 
in development for asthma. Small molecule antagonists of inflammatory mediators have been disappointing in 
asthma, but there has recently been great interest in blocking prostaglandin (PG) D2, which is released from mast 
cells and attracts Th2 cells and eosinophils via the receptor chemoattractant homologous receptor expressed on 
Th2 cells (CRTH2) (or DP2 receptors). PGD2 seems to be increased in patients with severe asthma who are not 
controlled on inhaled therapy.
122 
Several oral CRTH2 antagonists are now in development and have shown some 
clinical benefit.
123
 As discussed earlier, there are several broad-spectrum antiinflammatory treatments that target 
neutrophilic inflammation, so they may be effective in patients with severe asthma who do not respond well to 
corticosteroid therapy.
124
 Mast-cell activation is found in patients with severe asthma, suggesting that mast-cell 
inhibitors may be useful in these patients. As discussed earlier, omalizumab is useful in some patients with 
severe asthma and reduces exacerbations
66,67
 but cannot be used in patients with high circulating IgE 
concentrations, so antibodies with a higher affinity are now in development. Other drugs that target mast cells 
include c-kit and Syk inhibitors. 
SUMMARY 
There is no doubt that ICS have led to considerably improved asthma control and reduced asthma mortality in 
the Western world over the last 2 decades. ICS are particularly effective in combating Th2-driven inflammation 
featuring mast-cell and eosinophilic airway infiltration. Their effect   on   innate   immunity-driven   neutrophilic 
inflammation is poor and their ability to prevent airway remodeling and accelerated lung decline is highly 
controversial. Although ICS remain pivotal drugs in asthma management, research is needed to find drugs 
complementary to the combination ICS/LABA in refractory asthma and perhaps a new class of drugs as a first-
line treatment in mild to moderate noneosinophilic asthma (Fig. 1). 
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Fig. 1. Proposed strategy for asthma mainstay treatment according to the degree of severity and the sputum 
inflammatory phenotype. CRTH2, chemoattractant homologous receptor expressed on Th2 cells, also known as 
DP2 receptor, a receptor for PGD2; ICS, inhaled corticosteroids; LABA, long-acting β2-agonists; LTRA, 
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